DeutschNewstral
Article
Mmarketwatch.com on 2022-11-30 17:40
5 things to know about the new Alzheimer’s drug — including why it may be risky for people who take blood thinners4 min read
Related news
- BBiogen’s Alzheimer’s Drug Has Another Shot at Success3 min readbarrons.com
- MWhat to know about the Alzheimer’s drug data coming out this week3 min readmarketwatch.com
- MCaring for someone with Alzheimer’s? This pilot program is making impressive gains.3 min readmarketwatch.com
- BBiogen Soars 46% on Alzheimer’s Drug Trial. Mizuho Says the Stock Is a Buy.2 min readbarrons.com
- MEli Lilly's Alzheimer’s treatment shows promise in early stages of disease — but safety concerns remain4 min readmarketwatch.com
- BAnother Setback for Biogen’s Controversial Alzheimer’s Drug1 min readbarrons.com
- BBiogen Announces New Trial for Alzheimer’s drug Aduhelm2 min readbarrons.com
- MBiogen and Eisai make plans to take another Alzheimer's drug to the FDA3 min readmarketwatch.com
- BAn Alzheimer’s Drug’s Big Surprise: How It Reset the Playing Field4 min readbarrons.com
- BBitcoin Erases 2021 Gains. It's the 'Ultimate Risky Asset Right Now.'2 min readbarrons.com
- MWhy the corporate debt boom isn't less risky because stocks are near records3 min readmarketwatch.com
- MRegulators have the authority to act now to stop runs on risky stablecoins 4 min readmarketwatch.com
- BBiogen and Eisai Strengthen Lead in Alzheimer’s Drug Race. The Stocks Are Rising. 2 min readbarrons.com
Medicare to Review Coverage for New Alzheimer’s Drug Aduhelm3 min readwsj.com- Biogen Sees Heavy Patient Interest in New Alzheimer’s Drug4 min readwsj.com
- BBiogen After the Alzheimer’s Drug Debacle: Time to Sell the Parts? 4 min readbarrons.com